{"id":"hum0381","version":1,"url":"https://humandbs.dbcls.jp/research/hum0381/v1","datePublished":"2023-01-05","versions":[{"version":1,"datePublished":"2023-01-05"}],"title":{"ja":"切除不能または再発胸腺癌に対するニボルマブの多施設共同第II相試験（NCCH1505）附随研究","en":"A biomarker study of a multicenter Phase II Trial of Nivolumab for Unresectable or Recurrent Thymic Carcinoma (NCCH1505)"},"summary":{"aims":{"ja":"血液、腫瘍組織標本を用いて、病理学的評価、薬物動態・分子イメージング解析、ゲノム解析、免疫モニタリングを行い、多角的な解析を行うことで、切除不能または再発胸腺がん患者における、ニボルマブの有効性と安全性に関するバイオマーカーの探索を行う。","en":"We explore biomarkers of nivolumab efficacy and safety in patients with unresectable or recurrent thymic carcinoma. In order to perform multifaceted analysis using blood and tumor tissue specimens, pathological evaluation, pharmacokinetic, and molecular imaging analysis, genomic analysis, and immunomonitoring were performed."},"methods":{"ja":"末梢血血球成分を用いて、Immuno-PGxパネルによる免疫関連遺伝子（SNV、inDelの解析と機能予測、コピー数変異解析など）の解析を行う。","en":"We analyze immune-related genes (SNV, indel analysis and function prediction, copy number mutation analysis, etc.) by Immuno-PGx panel with peripheral blood cell components."},"targets":{"ja":"NCCH1505試験へ参加している胸腺がん患者のうち、Immuno-pharmacogenomics（Immuno-PGx）を行った15症例","en":"15 patients with thymic carcinoma participating in the NCCH1505 study"},"url":{"ja":null,"en":null}},"listingSummary":{"methods":{"ja":"配列決定","en":"Sequencing"},"targets":{"ja":"胸腺癌：15症例\n（日本人）","en":"thymic carcinoma: 2 cases\n(Japanese)"},"typeOfData":{"ja":"NGS\n（Target Capture）","en":"NGS\n(Target Capture)"}},"releaseNote":{"ja":"胸腺がん15症例の末梢血から抽出したDNAを用いた、Immuno-PGxパネルによるTarget Capture Sequencing解析データをfastqファイルにて提供する。","en":"DNAs extracted from peripheral blood cells of 15 patients with thymic carcinoma were used for the target capture sequencing analysis (Immuno-PGx panel). Fastq files are provided."},"dataProviders":[{"name":{"ja":"堀之内 秀仁","en":"Hidehito Horinouchi"},"organization":{"name":{"ja":"国立がん研究センター中央病院 呼吸器内科","en":"Department of Thoracic Oncology, Nantional Cancer Center Hospital"}}}],"researchProjects":[],"grants":[{"title":{"ja":"胸腺癌、胸腺腫に対する抗PD-1抗体ニボルマブ適応拡大のための研究","en":"Study to Expand Indication of Nivolumab, an Anti-PD-1 Antibody, for Thymic Carcinoma and Thymoma"},"agency":{"ja":"日本医療研究開発機構（AMED） 革新的がん医療実用化研究事業","en":"Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED)"},"grantIds":["JP17ck0106161"]}],"relatedPublications":[{"title":"Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma","doi":"https://doi.org/10.3389/fonc.2022.966527","datasets":["JGAD000715"]}],"datasets":["JGAD000715"],"controlledAccessUsers":[]}